Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias.
[en] ("[en] INTRODUCTION: Aggregation of tau is a hallmark of many neurodegenerative diseases, and tau imaging with positron emission tomography (PET) may allow early diagnosis and treatment monitoring. We assessed binding of the PET tracer [18F]AV-1451 in a range of dementias.
METHODS: Phosphorimaging was used to quantify binding to postmortem brain tissue from 33 patients with different, histopathologically characterized, neurodegenerative dementias.
RESULTS: [18F]AV-1451 showed high specific binding in cases with Alzheimer's disease (AD), moderate binding in Pick's disease and frontotemporal dementia with parkinsonism-17, and low but displaceable binding in corticobasal degeneration, progressive supranuclear palsy, non-tau proteinopathies, and in controls without pathology. Tracer binding did not correlate with tau load within disease groups.
DISCUSSION: [18F]AV-1451 binds to tau in AD, and some other tauopathies. However, evidence for a non-tau binding site and lack of correlation between tracer binding and antibody staining suggest that reliable quantification of tau load with this tracer is problematic.","[en] ","")
Disciplines :
Chemistry Radiology, nuclear medicine & imaging Neurology
Author, co-author :
Sander, Kerstin; Institute of Nuclear Medicine and Department of Chemistry, University College London, London, UK
Lashley, Tammaryn; Institute of Neurology, Department of Molecular Neuroscience, Queen Square Brain Bank, University College London, London, UK
Gami, Priya; Institute of Neurology, Department of Molecular Neuroscience, Queen Square Brain Bank, University College London, London, UK
Gendron, Thibault ; Université de Liège - ULiège > Département de chimie (sciences) > Chimie organique-nucléaire ; Institute of Nuclear Medicine and Department of Chemistry, University College London, London, UK
Lythgoe, Mark F; Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, London, UK
Rohrer, Jonathan D; Institute of Neurology, Department of Neurodegenerative Disease, Dementia Research Centre, University College London, London, UK
Schott, Jonathan M; Institute of Neurology, Department of Neurodegenerative Disease, Dementia Research Centre, University College London, London, UK
Revesz, Tamas; Institute of Neurology, Department of Molecular Neuroscience, Queen Square Brain Bank, University College London, London, UK
Fox, Nick C; Institute of Neurology, Department of Neurodegenerative Disease, Dementia Research Centre, University College London, London, UK
Årstad, Erik; Institute of Nuclear Medicine and Department of Chemistry, University College London, London, UK. Electronic address: e.arstad@ucl.ac.uk
Language :
English
Title :
Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias.
Publication date :
November 2016
Journal title :
Alzheimer's and Dementia: the Journal of the Alzheimer's Association
ARUK - Alzheimer’s Research UK NIHR - National Institute for Health Research
Funding text :
The authors thank Avid Radiopharmaceuticals Inc. for providing labeling precursors and methods for the radiosynthesis of [ 18 F]AV-1451. The authors acknowledge funding by the Leonard Wolfson Experimental Neurology Centre (K.S. and P.G.), Alzheimer's Research UK (T.L.; ARUK-SRF2015-2), UCL Business (T.G.), and the NIHR Queen Square Dementia Biomedical Research Unit . This work was undertaken at UCLH/UCL, which is funded in part by the Department of Health's NIHR Biomedical Research Centres funding scheme.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
[1] Spillantini, M.G., Goedert, M., Tau pathology and neurodegeneration. Lancet Neurol 12 (2013), 609–622.
[2] Seelaar, H., Rohrer, J.D., Pijnenburg, Y.A., Fox, N.C., van Swieten, J.C., Clinical, genetic and pathological heterogeneity of frontotemporal dementia: A review. J Neurol Neurosurg Psychiatry 82 (2011), 476–486.
[3] Villemagne, V.L., Okamura, N., In vivo tau imaging: Obstacles and progress. Alzheimers Dement 10:3 Suppl (2014), S254–S264.
[5] Cairns, N.J., Bigio, E.H., Mackenzie, I.R., Neumann, M., Lee, V.M., Hatanpaa, K.J., et al., Consortium for Frontotemporal Lobar Degeneration. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: Consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 114 (2007), 5–22.
[6] Noble, W., Hanger, D.P., Miller, C.C., Lovestone, S., The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol, 4, 2013, 83.
[8] Arriagada, P.V., Growdon, J.H., Hedley-Whyte, E.T., Hyman, B.T., Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42 (1992), 631–639.
[9] Ossenkoppele, R., Schonhaut, D.R., Baker, S.L., O'Neil, J.P., Janabi, M., Ghosh, P.M., et al. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann Neurol 77 (2015), 338–342.
[10] Xia, C.F., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L.F., Kasi, D., et al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement 9 (2013), 666–676.
[11] Chien, D.T., Szardenings, A.K., Bahri, S., Walsh, J.C., Mu, F., Xia, C., et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis 38 (2012), 171–184.
[12] Shah, M., Catafau, A.M., Molecular imaging insights into neurodegeneration: Focus on tau PET radiotracers. J Nucl Med 55 (2014), 871–874.
[13] Mirra, S.S., Heyman, A., McKeel, D., Sumi, S.M., Crain, B.J., Brownlee, L.M., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41 (1991), 479–486.
[14] Braak, H., Braak, E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82 (1991), 239–259.
[15] Thal, D.R., Rueb, U., Orantes, M., Braak, H., Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58 (2000), 1791–1800.
[16] Montine, T.J., Phelps, C.H., Beach, T.G., Bigio, E.H., Cairns, N.J., Dickson, D.W., et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: A practical approach. Acta Neuropathol 123 (2012), 1–11.
[17] Dickson, D.W., Hauw, J.J., Agid, Y., Litvan, I., Progressive supranuclear palsy and corticobasal degeneration. Dickson, D.W., Weller, R.O., (eds.) Neurodegeneration: The molecular pathology of dementia and movement disorders, 2011, Wiley-Blackwell, Chichester, 135–155.
[18] Mackenzie, I.R., Neumann, M., Baborie, A., Sampathu, D.M., Du Plessis, D., Jaros, E., et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 122 (2011), 111–113.
[19] McKeith, I.G., Dickson, D.W., Lowe, J., Emre, M., O'Brien, J.T., Feldman, H., et al., Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 65 (2005), 1863–1872.
[20] Lashley, T., Rohrer, J.D., Bandopadhyay, R., Fry, C., Ahmed, Z., Isaacs, A.M., et al. A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain 134:Pt 9 (2011), 2548–2564.
[21] Xiong, H., Hoye, A.T., Fan, K.H., Li, X., Clemens, J., Horchler, C.L., et al. Facile route to 2-fluoropyridines via 2-pyridyltrialkylammonium salts prepared from pyridine N-oxides and application to 18F-labeling. Org Lett 17 (2015), 3716–3729.
[22] Schneider, C.A., Rasband, W.S., Eliceiri, K.W., NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9 (2012), 671–675.
[23] de Silva, R., Lashley, T., Gibb, G., Hanger, D., Hope, A., Reid, A., et al. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol Appl Neurobiol 29 (2003), 288–302.
[24] Augustinack, J.C., Schneider, A., Mandelkow, E.M., Hyman, B.T., Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 103 (2002), 26–35.
[25] Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79 (2013), 1094–1108.
[26] Varrone, A., Steiger, C., Schou, M., Takano, A., Finnema, S.J., Guilloteau, D., et al. In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE-PE21, a new dopamine transporter PET radioligand. Synapse 63 (2009), 871–880.
[27] Kanazawa, M., Shimohata, T., Toyoshima, Y., Tada, M., Kakita, A., Morita, T., et al. Cerebellar involvement in progressive supranuclear palsy: A clinicopathological study. Mov Disord 24 (2009), 1312–1318.
[29] Clavaguera, F., Akatsu, H., Fraser, G., Crowther, R.A., Frank, S., Hench, J., et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A 110 (2013), 9535–9540.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
